Cellectar Biosciences Inc

Cellectar Biosciences Inc. is a privately held company based in Florham Park, New Jersey, with 39 employees. The company focuses its efforts on researching and developing innovative cancer treatments. Cellectar Biosciences specializes in the creation of Phospholipid Drug Conjugate™ (PDC) drug delivery systems. These PDCs are designed to specifically target cancer cells, aiming to enhance treatment efficacy while minimizing side effects due to reduced off-target activity. Their product pipeline includes CLR 131, a small-molecule PDC designed to deliver the radioisotope iodine-131 with precision. Cellectar is also developing proprietary preclinical PDC chemotherapeutic programs and collaborating on multiple other PDC assets. Currently, they are conducting a global Phase 2 Part B clinical trial (CLOVER-WaM) focused on Waldenstrom's macroglobulinemia (WM) patients who have received at least two prior lines of therapy. Interested parties can learn more about Cellectar Biosciences and their work at www.cellectar.com and www.wmclinicaltrial.com. Follow them on social media platforms like Twitter, LinkedIn, Facebook, and YouTube for updates and engagement.